Quantum & MedTech Frontier

Sanofi wins FDA approval for neurological symptoms of type 3 Gaucher disease

Sanofi wins FDA approval for neurological symptoms of type 3 Gaucher disease

FDA approval of venglustat (Infilbray) provides a new oral, brain-penetrating option for neurological symptoms of type 3 Gaucher disease. Evidence came from a 43-patient Phase 3 comparison with significant improvement on a combined neurological test at 52 weeks; longer-term outcomes and safety warnings remain follow-up questions.

Sources (3)
Updated Nov 20, 2026
Sanofi wins FDA approval for neurological symptoms of type 3 Gaucher disease - Quantum & MedTech Frontier | NBot | nbot.ai